| Literature DB >> 30683065 |
Alejandra de-la-Torre1, Juanita Valdés-Camacho2, Clara López de Mesa3, Andrés Uauy-Nazal3, Juan David Zuluaga2, Lina María Ramírez-Páez3, Felipe Durán4,3, Elizabeth Torres-Morales2, Jessica Triviño2, Mateo Murillo2, Alba Cristina Peñaranda3, Juan Carlos Sepúlveda-Arias5, Jorge Enrique Gómez-Marín2.
Abstract
BACKGROUND: Making a definite diagnosis of infectious uveitis is a challenging task because many other infectious, and non-infectious uveitis, may have similar non-specific symptoms and overlapping clinical appearances. Co-infections in immunocompetent patients are not frequently proved with traditional serologic-diagnostic tools.Entities:
Keywords: Co-infections; Diagnosis; Goldmann-Witmer; Immunocompetent; Ocular toxoplasmosis; PCR
Mesh:
Substances:
Year: 2019 PMID: 30683065 PMCID: PMC6347798 DOI: 10.1186/s12879-018-3613-8
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Diagnostic flowchart, classification of diagnosis and clinical follow-up. Flow chat for the diagnosis of confirmed ocular toxoplasmosis, undetermined toxoplasmosis, without ocular toxoplasmosis and co-infections: Specific PCR and GWC analyses in aqueous humor samples
Clinical characteristics of patients with uveitis according to final diagnosis
| Characteristics of patients | Median (range) or number/total (percent) in COT patients ( | Median (range) or number/total (percent) in UOT patients ( | Median (range) or number/total in OU patients ( | Median (range) or number/total in COINF patients ( | p |
|---|---|---|---|---|---|
| Age | 37,5 (13–70) | 30 (19–74) | 34 (17–79) | 50,2 (16–79) | 0,523 |
| Gender Female | 10/22 (45,5%) | 6/16 (37,5%) | 14/23 (60,9%) | 2/5 (40% | 0,492 |
| Localization of uveitis (anterior, posterior and panuveitis) | 0/22 (0%) anterior | 1/16 (6,3%) anterior | 5/23 (21,7%) anterior | 0/5 (0%) anterior |
|
| Bilateral involvement | 3/22 (13,6%) | 2/16 (12,5%) | 7/23 (30,4%) | 2/5 (40%) | 0,351 |
| Cataract | 6/22 (27,2%) | 4/16 (25%) | 8/23 (34,7%) | 1/5 (20%) | 0,655 |
| Papillitis | 3/22 (13,6%) | 1/16 (6,3%) | 4/23 (17,4%) | 1/5 (20%) | 0,539 |
| Total number of scars (both eyes) | 2,5 (1–11) | 2 (1–18) | 1,5 (1–4) | 2,5 (2–3) | 0,800 |
| Number of inflammatory cells in vitreous humor | 2 (0–4) | 0,5 (0–4) | 1 (0–4) | 2 (0–4) | 0,403 |
| Median size of scars in disk diameters | 1,53 (1–6) | 1 (1–4) | 0,9 (1–3) | 1,3 (1–2) | 0,157 |
| Median number of recurrences episodes | 1,81 (0–10) | 1 (0–4) | 1,52 (0–10) | 0,6 (0–2) | 0,658 |
| Number (%) of IgM serological test positive for virus (EBV, CMV, HVS1, HVS2) | 2/22 (9%) | 2/16 (18,8%) | 5/23 (21,7%) | 0/5 (0%) | 0,716 |
| Number of patients with intraocular pressure > 20 mmHg | 4/22 (18,2%) | 1/16 (6,3%) | 2/23 (8,7%) | 1/5 (12,5%) | 0,236 |
| Number of patients (%) with change of treatment after diagnosis | 3/22 (13,6%) | 1/16 (6,3%) | 13/23 (56.5%) | 3/5 (60%) |
|
| Significant clinical improvement after treatment change | 3/3 (100%) | 1/1 (100%) | 12/13 (92,3%) | 3/3 (100%) | – |
| Significant clinical improvement after 6 months of treatment (regardless of whether there was change or continuation) | 21/22 (95.4%) | 14/16 (87.5%) | 20/23 (86.95%) | 4/5 (80%) | – |
| IgG for Toxoplasmosis: qualitative | 22/22 (100%) | 16/16 (100%) | 3/23 (13%) | 5/5 (100%) | – |
| IgM for Toxoplasmosis: qualitative | 3/22 (13.6%) | 0/16 (0%) | 1/23 (4.34%) | 0/5 (0%) | – |
| IgM for EBV: qualitative | 2/22 (9%) | 2/16 (33.3%) | 3/23 (13%) | 0/5 (0%) | – |
| IgM for CMV: qualitative | 0/22 (0%) | 0/16 (0%) | 0/23 (0%) | 0/5 (0%) | – |
| IgM for HSV-1: qualitative | 0/22 (0%) | 0/16 (0%) | 2/23 (8.6%) | 0/5 (0%) | – |
| IgM for HSV-2: qualitative | 0/22 (0%) | 0/16 (0%) | 0/23 (0%) | 0/5 (0%) | – |
COINF Co-infection, COT Confirmed ocular toxoplasmosis, OU Other uveitis, UOT Undetermined ocular toxoplasmosis
*statistically significant difference (p< 0,05)
Results of GWC/PCR in patients with OT or UOT, according to the time elapsed since the onset of symptoms and to cell counts in AH
| Characteristics of patients with OT | GWC positive | GWC negative | PCR positive | PCR negative | ||
|---|---|---|---|---|---|---|
| Duration of symptoms before sampling in days. Median [range]. | 30 [2–230] | 25 [2–277] | 0.8261 | 48 [1–277] | 27 [2–230] | 0.6692 |
| Number of cells/μL of AH. | 2 [0–4] | 1 [0–4] | 0.5066 | 1.25 [0–3] | 2 [0–3] | 0.1903 |
AC Anterior chamber, GWC Goldmann–Witmer coefficient, AH Aqueous humor, PCR Polymerase chain reaction
GWC/PCR in AH in confirmed OT according to the onset of symptoms and the treatment before sampling
| Characteristics of patients with OT | GWC+/PCR+ | GWC+/PCR- | GWC-/PCR+ |
|---|---|---|---|
| Duration of symptoms before sampling in days. Mean ± SD. | 48.6 ± 51 | 55.2 ± 67 | 163 ± 160 |
| Duration treatment before sampling (days). Mean ± SD. | 17.3 ± 11.3 | 21.2 ± 18.3 | - |
GWC Goldmann–Witmer coefficient, PCR Polymerase chain reaction
2 patients GWC + and no PCR data. 1 patient PCR + and no GCW data. (Not included in the table)